Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 11Thoracic 8CNS 6Gastrointestinal 4Genitourinary 3Breast 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × enzastaurin × Breast × Clear all
NCT00536939 2020-09-24

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
2 enrolled 5 charts
Breast

Breast Neoplasms

NCT00437294 2020-08-10

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Eli Lilly and Company

Phase 2 Terminated
86 enrolled 20 charts
Breast

Breast Neoplasms

NCT00451555 2019-11-01

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

Eli Lilly and Company

Phase 2 Completed
156 enrolled 15 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡